MIKAELL ALEXANDRE GOUVEA FARIA

Dr. MIKAELL ALEXANDRE GOUVEA FARIA


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2026 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
João Daniel de Souza MenezesJoão Daniel de Souza Menezes
João Daniel de Souza Menezes
Matheus QuerinoMatheus Querino
Matheus Querino
ESEmerson Roberto dos Santos
Emerson Roberto dos Santos
Stela Regina Pedroso Vilela Torres de CarvalhoStela Regina Pedroso Vilela Torres de Carvalho
Stela Regina Pedroso Vilela Torres de Carvalho
MFMIKAELL ALEXANDRE GOUVEA FARIA
MIKAELL ALEXANDRE GOUVEA FARIA
JAJúlio César André
Júlio César André
Purpose: This scoping review aimed to systematically map and critically describe the current evidence on the role of the gut microbiome as a biomarker in oncology, including microbiome-based predictive models and microbial signatures associated with treatment response, toxicity and disease course, and to identify methodological gaps and challenges for clinical translation in precision medicine. Methods: This scoping review was conducted following the Joanna Briggs Institute (JBI) guidelines for scoping reviews and reported according to the PRISMA Extension for Scoping Reviews (PRISMA-ScR). The search was performed in five electronic databases (PubMed/MEDLINE, Web of Science, Scopus, SciELO, and LILACS) using a structured PICO strategy. Studies involving adult cancer patients undergoing systemic oncological therapies (including chemotherapy, immunotherapy and combined regimens), with gut microbiome analysis and the investigation, development or validation of microbiome-based biomarkers or predictive models, were included. Results: The literature demonstrates that specific microbial taxa significantly influence the efficacy of immunotherapies (e.g., AUCs up to 0.88 for ICI response prediction) and chemotherapies, and modulate toxicity (e.g., mucositis reduction from 47.1% to 25% with probiotics). Microbiome-based predictive models often outperform clinical markers (e.g., AUC of 0.88 vs. 0.50 in urothelial carcinoma), and variations in microbiota composition can predict disease progression. The literature mapping of the 20 included studies demonstrates that specific microbial taxa significantly influence the efficacy of immunotherapies (e.g., AUCs up to 0.88 for ICI response prediction) and chemotherapies. Regarding toxicity, while the review focuses on baseline biomarkers, exploratory intervention-based data were addressed, showing that a probiotic cocktail reduced Grade 3–4 oral mucositis from 47.1% to 25%. Furthermore, microbiome-based predictive models demonstrated enhanced discriminatory accuracy in predicting patient outcomes compared to standard clinical classification markers alone (e.g., achieving an Area Under the Curve [AUC] of 0.88 vs. 0.50 for clinical factors in urothelial carcinoma), though these models remain in early exploratory stages. Conclusion: Overall, the evidence suggests a growing interest and potential for microbiome-based predictive models in oncology; however, their clinical translation remains limited by methodological heterogeneity, insufficient external validation, and incomplete mechanistic understanding.

27 February 2026 in Obesity Surgery
Verified
Journal Article
Open access
PDF file
Matheus QuerinoMatheus Querino
Matheus Querino
MFMIKAELL ALEXANDRE GOUVEA FARIA
MIKAELL ALEXANDRE GOUVEA FARIA
João Daniel de Souza MenezesJoão Daniel de Souza Menezes
João Daniel de Souza Menezes
Metabolic Bariatric Surgery (MBS), an effective intervention for severe obesity, elevates the risk of cholelithiasis (CL) due to rapid weight loss and altered biliary metabolism. Ursodeoxycholic acid (UDCA) is increasingly investigated as a prophylactic strategy to mitigate this complication. This scoping review aimed to map and compare UDCA dosage, duration, and initiation timing protocols for CL prevention after MBS. A review was conducted across PubMed/MEDLINE, Web of Science, and Scopus, selecting 10 articles published between 2014 and 2023. The analyzed literature consistently indicates that UDCA prophylaxis significantly reduced CL incidence from 25 to 40% in control groups to 1.4–10.8% in treated groups. Studies commonly reported dosages of 500–600 mg/day for 6 months postoperatively were common, with early initiation being crucial. Efficacy is evident for both Sleeve Gastrectomy (SG) and Roux-en-Y Gastric Bypass (RYGB), with CL relative risks between 0.13 and 0.36. The evidence demonstrates UDCA safety, efficacy, and cost-effectiveness. Collectively, the literature supports UDCA as an effective and safe prophylactic measure against post-MBS cholelithiasis. The identified heterogeneity in protocols underscores the need for standardization to optimize clinical application.

26 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RGRodrigo Galhardi Gasparini
Rodrigo Galhardi Gasparini
Carlos TaxoneraCarlos Taxonera
Carlos Taxonera
AJAntônio José Tibúrcio Alves Júnior
Antônio José Tibúrcio Alves Júnior
BSBianca Loyo Pona Schiavetti
Bianca Loyo Pona Schiavetti
FPFrancisco Guilherme Cancela e Penna
Francisco Guilherme Cancela e Penna
MFMIKAELL ALEXANDRE GOUVEA FARIA
MIKAELL ALEXANDRE GOUVEA FARIA
Background/Objectives: Golimumab has proven efficacy in inducing and maintaining remission in moderate-to-severe ulcerative colitis (UC). This study evaluated the short-term and long-term effectiveness and safety of golimumab for the treatment of patients with active UC in Brazil. Methods: This observational, multicenter, retrospective, cohort study included patients with moderate-to-severe UC treated with golimumab. The primary outcome was corticosteroids-free clinical remission at weeks 24 and 54, defined as a partial Mayo score (PMS) of 0 or 1, without the need for corticosteroids (CS,) in continued treatment with golimumab. Secondary outcomes were clinical response, defined as a reduction in PMS of 50% or 3 points, and endoscopic remission, defined as a Mayo endoscopic subscore of 0. We also evaluated persistence with golimumab during follow-up. Results: Seventy-three patients were enrolled in the study. The rates of CS-free remission at weeks 24 and 54 were 43.8% and 63%, respectively. Clinical response was achieved in 50.7% and 71.2% of patients at weeks 24 and 48, respectively. Among patients undergoing endoscopic evaluation, CS-free endoscopic remission was observed in 80.8% of patients at week 24 and in 84.4% at week 54. The cumulative probability of retaining golimumab was 86.1% (95% CI 78–94) at 54 weeks. Adverse events leading to golimumab discontinuation occurred in three patients (4.1%). Conclusions: Golimumab was effective and safe as induction and maintenance therapy in patients with moderate-to-severe ulcerative colitis, leading to a high rate of persistence with golimumab maintenance after 1 year of follow-up.